Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

10.33 

0.07 0.7%

as of May 23 '19

52 Week Range:

9.91 16.51


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Mitsubishi Tanabe Pharma Corporation manufactures and sells pharmaceuticals in Japan, Europe, North America, other Asian countries, and internationally. The company offers drugs for autoimmune, diabetes, kidney, central nervous system, and other disease treatment; and vaccines, as well as sells generic drugs and over-the-counter (OTC) products. It offers Remicade for treatment of rheumatoid arthritis (RA), Crohn's, Bechet's, psoriasis, ankylosing spondylitis, and ulcerative colitis diseases; Simponi for the treatment of RA; Kremezin for the treatment of chronic renal failure; and Tenelia for type II diabetes mellitus. The company also provides Ceredist for the treatment of spinocerebellar degeneration; Depas, an anti-anxiety agent; Lexapro, an anti-depressant agent; Imusera for multiple sclerosis; Radicut, a cerebral neuroprotectant; Talion for the treatment of allergic disorders; Maintate for the treatment of hypertension, angina pectoris, ventricular extrasystole, chronic heart failure, and atrial fibrillation; Urso that improves hepatic, biliary, and digestive functions; and Anplag, an anti-platelet agent. In addition, it offers TETRABIK, a vaccine for diphtheria, pertussis, tetanus, and poliomyelitis; Varicella vaccine for the prevention of chicken pox; Influenza vaccine; Mearubik, a vaccine for measles and rubella; and JEBIK V for the prevention of Japanese encephalitis. Further, the company provides OTC products, including agents for the treatment of skin conditions; tonic and nutritional supplements; herbal and digestive medicines; and oral agents for allergic rhinitis and recurrent vaginal candidiasis. Additionally, it provides information about pharmaceuticals; and invests in bio-ventures. The company has collaborations with Dyadic International, Inc.; Hitachi Ltd.; and HitGen Ltd. The company was founded in 1678 and is headquartered in Osaka, Japan. The company is a subsidiary of Mitsubishi Chemical Holdings Corporation.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Equity (BVPS) 8.86
9.59
10.47
11.51
10.79
9.73
10.81
11.52
12.69
12.05
growth rate 8.2% 9.2% 9.9% -6.3% -9.8% 11.1% 6.6% 10.2% -5.0%
Earnings BIT 59,119.00
67,133.00
94,907.00
94,762.00
77,412.00
56,273.00
growth rate 13.6% 41.4% -0.2% -18.3% -27.3%
Avg.PE 21.39
17.12
13.98
12.25
growth rate -20.0% -18.3% -12.4%
ROA 3.28
3.76
4.67
4.76
4.97
5.18
4.35
6.07
7.44
5.70
growth rate 14.6% 24.2% 1.9% 4.4% 4.2% -16.0% 39.5% 22.6% -23.4%
ROE 4.06
4.57
5.55
5.55
5.72
6.00
5.08
7.08
8.55
6.65
growth rate 12.6% 21.4% 0.0% 3.1% 4.9% -15.3% 39.4% 20.8% -22.2%
ROIC 3.79
4.36
5.37
5.39
5.57
5.86
4.97
6.94
8.54
6.65
growth rate 15.0% 23.2% 0.4% 3.3% 5.2% -15.2% 39.6% 23.1% -22.1%
Cur. Ratio 4.09
4.43
4.46
6.03
5.54
6.60
5.73
7.20
7.73
6.01
growth rate 8.3% 0.7% 35.2% -8.1% 19.1% -13.2% 25.7% 7.4% -22.3%
Quick Ratio 3.03
3.28
3.38
4.60
2.49
3.14
2.84
3.95
6.61
5.11
growth rate 8.3% 3.1% 36.1% -45.9% 26.1% -9.6% 39.1% 67.3% -22.7%
Leverage 1.24
1.19
1.19
1.15
1.16
1.16
1.18
1.15
1.14
1.19
growth rate -4.0% 0.0% -3.4% 0.9% 0.0% 1.7% -2.5% -0.9% 4.4%
Balance Sheet Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Acct.Receivable 129,825.00
123,498.00
130,287.00
121,249.00
116,856.00
123,537.00
116,951.00
growth rate -4.9% 5.5% -6.9% -3.6% 5.7% -5.3%
Acct.Payable 38,072.00
33,986.00
34,620.00
32,737.00
35,741.00
35,631.00
31,477.00
growth rate -10.7% 1.9% -5.4% 9.2% -0.3% -11.7%
Cur.Assets 476,686.00
540,492.00
603,649.00
657,253.00
683,759.00
585,525.00
588,433.00
growth rate 13.4% 11.7% 8.9% 4.0% -14.4% 0.5%
Total Assets 866,774.00
886,476.00
929,301.00
930,242.00
984,537.00
1,047,621.00
1,056,286.00
growth rate 2.3% 4.8% 0.1% 5.8% 6.4% 0.8%
Cash 20,281.00
27,187.00
50,203.00
142,674.00
113,215.00
127,030.00
111,850.00
growth rate 34.1% 84.7% 184.2% -20.7% 12.2% -12.0%
Inventory 92,783.00
93,700.00
85,091.00
75,631.00
79,168.00
81,998.00
75,559.00
growth rate 1.0% -9.2% -11.1% 4.7% 3.6% -7.9%
Cur.Liabilities 86,118.00
81,837.00
105,399.00
91,309.00
85,262.00
97,370.00
91,699.00
growth rate -5.0% 28.8% -13.4% -6.6% 14.2% -5.8%
Liabilities 113,852.00
108,639.00
128,867.00
113,529.00
113,107.00
152,794.00
145,954.00
growth rate -4.6% 18.6% -11.9% -0.4% 35.1% -4.5%
LT Debt 958.00
894.00
713.00
581.00
420.00
150.00
growth rate -6.7% -20.3% -18.5% -27.7% -64.3%
Equity 766,046.00
788,979.00
805,931.00
860,505.00
882,808.00
897,604.00
growth rate 3.0% 2.2% 6.8% 2.6% 1.7%
Common Shares 561.00
561.00
561.00
561.00
561.00
561.00
561.00
561.00
561.00
561.00
50,000.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 8,812.7%
Cash Flow Statement Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Capital Expenditures 8,681.00
12,302.00
12,976.00
11,861.00
14,271.00
6,416.00
5,730.00
growth rate 41.7% 5.5% -8.6% 20.3% -55.0% -10.7%
Cash Dividends 22,439.00
22,439.00
24,684.00
26,927.00
37,017.00
31,403.00
growth rate 0.0% 10.0% 9.1% 37.5% -15.2%
Cash From OA 60,589.00
69,896.00
68,167.00
65,188.00
59,785.00
66,943.00
41,460.00
growth rate 15.4% -2.5% -4.4% -8.3% 12.0% -38.1%
FCF per Share 0.52
0.21
0.76
0.41
0.79
0.65
0.60
1.11
0.25
0.69
growth rate -59.6% 261.9% -46.1% 92.7% -17.7% -7.7% 85.0% -77.5% 176.0%
FCF 38,083.00
14,605.00
50,359.00
26,496.00
49,766.00
55,556.00
53,688.00
52,174.00
41,181.00
42,196.00
35,730.00
growth rate -61.7% 244.8% -47.4% 87.8% 11.6% -3.4% -2.8% -21.1% 2.5% -15.3%
Income Statement Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Sales 419,179.00
412,675.00
415,124.00
431,701.00
423,977.00
433,855.00
424,767.00
growth rate -1.6% 0.6% 4.0% -1.8% 2.3% -2.1%
Op.Income 41,953.00
59,119.00
67,133.00
94,907.00
94,762.00
77,412.00
56,273.00
growth rate 40.9% 13.6% 41.4% -0.2% -18.3% -27.3%
IBT 72,441.00
62,677.00
84,312.00
96,059.00
78,764.00
50,439.00
growth rate -13.5% 34.5% 13.9% -18.0% -36.0%
Net Income 41,953.00
45,393.00
39,502.00
56,434.00
71,263.00
57,963.00
37,372.00
growth rate 8.2% -13.0% 42.9% 26.3% -18.7% -35.5%
EPS 47.28
53.91
67.27
69.54
74.67
80.92
70.41
105.72
127.03
103.35
growth rate 14.0% 24.8% 3.4% 7.4% 8.4% -13.0% 50.2% 20.2% -18.6%
Gross Profit 252,791.00
243,312.00
245,519.00
275,895.00
259,580.00
264,105.00
244,121.00
growth rate -3.8% 0.9% 12.4% -5.9% 1.7% -7.6%
R&D 70,405.00
69,600.00
75,293.00
64,783.00
79,083.00
86,533.00
growth rate -1.1% 8.2% -14.0% 22.1% 9.4%

Quarterly Statements

Item Name Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Earnings BIT 8,959.00
19,300.00
15,193.00
22,027.00
400.00
growth rate 115.4% -21.3% 45.0% -98.2%
Balance Sheet Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Acct.Receivable 123,537.00
124,225.00
125,106.00
140,635.00
116,900.00
growth rate 0.6% 0.7% 12.4% -16.9%
Acct.Payable 35,631.00
28,882.00
34,715.00
39,042.00
31,400.00
growth rate -18.9% 20.2% 12.5% -19.6%
Cur.Assets 585,525.00
563,830.00
589,181.00
583,984.00
588,400.00
growth rate -3.7% 4.5% -0.9% 0.8%
Total Assets 1,047,621.00
1,033,346.00
1,070,941.00
1,051,513.00
1,056,200.00
growth rate -1.4% 3.6% -1.8% 0.5%
Cash 127,030.00
106,498.00
122,088.00
109,186.00
111,800.00
growth rate -16.2% 14.6% -10.6% 2.4%
Inventory 81,998.00
76,324.00
74,664.00
66,313.00
75,500.00
growth rate -6.9% -2.2% -11.2% 13.9%
Cur.Liabilities 97,370.00
76,079.00
91,116.00
86,506.00
91,600.00
growth rate -21.9% 19.8% -5.1% 5.9%
Liabilities 152,794.00
132,541.00
149,805.00
141,014.00
146,000.00
growth rate -13.3% 13.0% -5.9% 3.5%
LT Debt 420.00
381.00
177.00
205.00
100.00
growth rate -9.3% -53.5% 15.8% -51.2%
Equity 882,808.00
888,321.00
908,216.00
898,360.00
897,500.00
growth rate 0.6% 2.2% -1.1% -0.1%
Common Shares 50,000.00
50,000.00
50,000.00
50,000.00
50,000.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Capital Expenditures 487.00
1,275.00
920.00
1,855.00
1,680.00
growth rate 161.8% -27.8% 101.6% -9.4%
Cash Dividends 15,701.00
15,701.00
15,702.00
15,702.00
growth rate 0.0% 0.0% 0.0%
Cash From OA 21,769.00
609.00
22,888.00
5,971.00
11,992.00
growth rate -97.2% 3,658.3% -73.9% 100.8%
FCF 21,282.00
-666.00
21,968.00
4,116.00
10,312.00
growth rate -100.0% 100.0% -81.3% 150.5%
Income Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Sales 94,542.00
105,351.00
104,359.00
122,769.00
92,200.00
growth rate 11.4% -0.9% 17.6% -24.9%
Op.Income 8,959.00
19,300.00
15,193.00
22,027.00
400.00
growth rate 115.4% -21.3% 45.0% -98.2%
IBT 8,528.00
19,741.00
15,079.00
21,745.00
-6,100.00
growth rate 131.5% -23.6% 44.2% -100.0%
Net Income 5,855.00
13,959.00
11,032.00
16,477.00
-4,000.00
growth rate 138.4% -21.0% 49.4% -100.0%
Gross Profit 59,024.00
63,001.00
60,575.00
69,702.00
50,800.00
growth rate 6.7% -3.9% 15.1% -27.1%
R&D 22,964.00
19,648.00
19,907.00
22,351.00
24,600.00
growth rate -14.4% 1.3% 12.3% 10.1%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.59)

YOY Growth Grade:

E (17.93)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 11.69 12.01
EPS / Growth 0.86

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 2.8%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 2.8% 2.8% 2.8%
Future PE 0.01 5.76 5.76
Future EPS 1.13 1.13 1.13
Value Price
MOS %
0.00
-100.0%
1.61
-84.4%
1.61
-84.4%
MOS Price 0.00 0.81 0.81
IRT 10.25 10.25 10.25

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.